Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACK-iPS study of allogeneic iPS cell-derived cartilage for knee articular cartilage damage
jRCTa050190104Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2020
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of allogeneic induced pluripotent stem cell-derived cartilage in chondral knee defect, sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety and Tumorigenicity. Started Nov 2020; status: completed.
02
Drugs
allogeneic induced pluripotent stem cell-derived cartilage
03
Conditions
chondral knee defect
Beyond the preview
Go deeper on jRCTa050190104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTa050190104.